GCL
FOLD

Glazer Capital LLC’s Amicus Therapeutics FOLD Stock Holding History

Glazer Capital LLC’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$184M Buy
12,722,749
+11,118,961
+693% +$159M 3.9% 5
2025
Q4 		$22.8M Buy
+1,603,788
New +$15.8M 0.6% 30

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Glazer Capital LLC's FOLD Position: Q1 2026 in Review

Glazer Capital LLC increased its Amicus Therapeutics (FOLD) stake by 693% in Q1 2026, buying an estimated $159M and bringing the position to 12,722,749 shares worth $184M. The position accounts for 3.9% of the portfolio, ranked #5.

Glazer Capital LLC first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Glazer Capital LLC held 12,722,749 shares of Amicus Therapeutics worth $184M as of Q1 2026.
  • Glazer Capital LLC bought 11,118,961 Amicus Therapeutics shares in Q1 2026, an estimated $159M.
  • Amicus Therapeutics made up 3.9% of Glazer Capital LLC's portfolio in Q1 2026, its #5 holding.
  • Glazer Capital LLC first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Glazer Capital LLC's 13F filing for Q1 2026, filed 14 May 2026.